The novel intranasal rCV-A3V multi-epitope vaccine safely induced robust humoral, mucosal, and cellular immune responses against EV-A71, CVA16, CVA6, and CVB3 in mice.
Does intranasal immunization with rCV-A3V induce broad immunogenicity against enteroviruses in mice?
The novel multivalent epitope vaccine rCV-A3V induces broad humoral, mucosal, and cellular immune responses against multiple enteroviruses in mice, showing potential as an HFMD vaccine candidate.
Absolute Event Rate: 0% vs 0%
Background/Objectives: Hand, foot, and mouth disease (HFMD) is a major public health concern primarily caused by human enterovirus A71 (EV-A71), coxsackievirus A16 (CVA16), coxsackievirus A6 (CVA6), and certain coxsackievirus B serotypes. Currently available EV-A71 vaccines lack cross-protective efficacy against other serotypes, highlighting the urgent need for multivalent and broadly effective enterovirus vaccines. Methods: Immunoinformatics approaches were used to predict highly immunogenic B-cell and T-cell epitopes, which were assembled to construct a novel multivalent epitope vaccine, rCV-A3V, followed by in silico validation. Recombinant protein expression was confirmed by Western blotting and immunofluorescence assays. The immunogenicity was evaluated in Balb/c mice following intranasal immunization. Results: A preliminary safety evaluation demonstrated that the rCV-A3V vaccine was well tolerated in the mouse model, with no abnormal changes in body weight observed after immunization. In addition, the target protein was successfully expressed. Intranasal immunization induced a strong Th1-biased immune response, robust serum neutralizing and IgG antibody responses, and pronounced mucosal immunity, including elevated sIgA and IgG levels in nasal lavage fluid, sIgA in feces, and substantial sIgA responses in milk. Dominant epitope peptides were also identified. Conclusions: The intranasal live attenuated rCV-A3V vaccine successfully induced humoral, mucosal, and cellular immune responses against EV-A71, CVA16, CVA6, and CVB3, demonstrating broad immunogenicity. These findings provide experimental evidence supporting its potential as a candidate vaccine for HFMD.
Zheng et al. (Thu,) reported a other. The novel intranasal rCV-A3V multi-epitope vaccine safely induced robust humoral, mucosal, and cellular immune responses against EV-A71, CVA16, CVA6, and CVB3 in mice.